BWS Financial downgrades SciClone Pharmaceuticals (Nasdaq: SCLN) from Buy to Hold.

BWS analyst says, "SCLN shares have been ascending since ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE